

Date: 13/09/2018

FREEDOM OF INFORMATION REQUEST FOI/014333 - Psoriasis patients

1. How many patients with plaque psoriasis in your Trust are currently being treated with unlicensed Fumaderm? -  
- None

2. How many patients with plaque psoriasis in your trust are currently being treated with Skilarence? - Due to the low numbers and to prevent the possibility of patients being identified if information is released into the public domain the Trust is not releasing the numbers

3. Is the Trust starting patients with plaque psoriasis on Skilarence? - Yes

a. If yes to Q3, how many patients in the last 6 months? - Due to the low numbers and to prevent the possibility of patients being identified if information is released into the public domain the Trust is not releasing the numbers

4. Is the Trust starting patients with psoriasis on unlicensed Fumaderm? - No

a. If yes to Q4, how many patients in the last 6 months?

5. Does the Trust intend to review all patients with plaque psoriasis taking unlicensed Fumaderm in order to move them to a licensed formulation where appropriate? - N/A as above there are no patients being treated on Fumaderm

6. Please describe the process in place to achieve Q5 and the anticipated completion date. - N/A

7. If the Trust does not intend to initiate Skilarence or review all patients with plaque psoriasis taking unlicensed Fumaderm, please provide an explanation why the Trust intends to continue with its current practice. - The Trust has initiated Skilarence, as above we do not have any patients on unlicensed Fumaderm therefore we do not need to review its practise.